+1-888-308-5802     
News Contact Us

Cipla launches generic version of Remdesivir at a price of ₹4,000

Author : Pankaj Singh | Published Date : 2020-07-10 

Cipla Limited, the multinational pharmaceutical company, has reportedly launched a generic version of the remdesivir drug (Cipremi) at a price of ?4,000 per 100 mg vial, making it among the least priced COVID-19 treatment available across the globe.

According to sources familiar with the knowledge of the matter, the company is looking to supply more than 80,000 vials within the first month. The company's move to introduce remdesivir drugs at ?4,000 per 100 mg vial price is in line with its philosophy of accelerating access and affordability. The drug will be available only through hospital and government channels to ensure equitable distribution.

Till now, remdesivir is the only drug treatment approved by the US FDA (Food and Drug Administration) under EUA (Emergency Use Authorization) for treating hospitalized COVID-19 patients.

Speaking on which, Cipla CEO and Executive VP Nikhil Chopra (India Business) said in the statement that the company is proud to introduce Cipremi today which is amongst the lowest priced drug globally. The company is aiming to supply more than 80,000 vials within the first month itself, states Mr. Chopra.

Mr. Chopra added that the company would be donating some amount of the drug as part of its efforts to aid the community in this time of need.

The DCGI (Drug Controller General of India) approved Cipla’s remdesivir for restricted emergency use in the nation as part of the faster approval process considering the unmet and urgent medical need. In May, regional Pharma companies Jubilant Life Sciences, Hetero, and Cipla entered into non-exclusive licensing agreements with Gilead Sciences Inc for manufacturing and distributing remdesivir in the nation.

Meanwhile, India’s first potential COVID-19 vaccine, Covaxin will soon enter human clinical trials. Developed by Hyderabad- based Bharat Biotech, the vaccine will be tested on more than 1,100 people in two phases. The company already announced the plan to register 375 participants to test the COVID-19 vaccine candidate this month.

Source Credit -https://www.livemint.com/news/india/coronavirus-vaccine-cipla-launches-generic-version-of-remdesivir-in-india-11594223346722.html

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

ABCorp to Launch EGA Manufacturing With HP Multi Jet Fusion Technology

Published Date: 2021-01-15         Author: Pankaj Singh

ABCorp (American Banknote Corporation), one of the leading manufacturing service providers in the United States., has recently declared the expansion of their Center of Excellence. The opening of the company’s new Additive Manufacturing Center at the site compliments the offering of highly bes... Read More

Binomo launches an online trading platform to garner better profits

Published Date: 2021-01-13         Author: Pankaj Singh

According to reliable sources, Binomo, a client-oriented trading company, has recently launched a safe online trading platform to generate more profits. The platform is designed to assist in real-time market analysis and its primary target audience includes individuals that are inclined towards enha... Read More

Infosys to boost digital transformation by introducing an AI platform

Published Date: 2021-01-12         Author: Pankaj Singh

Indian multinational IT company Infosys Limited has reportedly been making headways in digital exponential technologies, primarily in AI (Artificial Intelligence). Shifting from its conventional IT solutions, the tech giant has significantly expanded its cloud-based solutions portfolio amid the COVI... Read More

© 2021 Fractovia. All Rights Reserved